Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models

Kazuo Umezawa, Itaru Kojima, Siro Simizu, Yinzhi Lin, Hitomi Fukatsu, Naoki Koide, Yukiomi Nakade, Masashi Yoneda

研究成果: Review article査読

10 被引用数 (Scopus)

抄録

Increasing metabolic syndromes including type-2 diabetes mellitus, obesity, and steatohepatitis are serious problems in most countries in the world. Neurodegenerative diseases such as Alzheimer, Parkinson’s, and Huntington’s diseases are increasing in many countries. However, therapy for these diseases is not sufficient yet. Thus, effective chemotherapy for these diseases is being expected. Conophylline is an alkaloid isolated from the leaves of Ervatamia microphylla and related plants. It was found to induce beta-cell differentiation in the precursor pancreatic cells. Oral administration of this compound ameliorated type-2 diabetes mellitus model in mice and rats. Later, fibrosis of the pancreatic islets was found to be greatly reduced by conophylline in the pancreatic islets. It also inhibited chemically induced liver cirrhosis. Further study indicated that conophylline inhibited non-alcoholic steatohepatitis in the model mice. On the one hand, loss of autophagy often causes protein aggregation to give neural cell death. Conophylline was found to activate autophagy in cultured neural cells. Activation of autophagy ameliorated cellular models of Parkinson’s and Huntington’s diseases. Thus, conophylline is likely to be useful for the development of chemotherapy for metabolic and neurodegenerative diseases.

本文言語English
ページ(範囲)95-101
ページ数7
ジャーナルHuman Cell
31
2
DOI
出版ステータスPublished - 2018 4 1

ASJC Scopus subject areas

  • Cell Biology
  • Cancer Research

フィンガープリント 「Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル